Tiverton Asset Management LLC Has $6.58 Million Position in Gilead Sciences, Inc. (GILD)
Tiverton Asset Management LLC trimmed its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 21.7% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 92,917 shares of the biopharmaceutical company’s stock after selling 25,700 shares during the period. Tiverton Asset Management LLC’s holdings in Gilead Sciences were worth $6,577,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors also recently bought and sold shares of GILD. Pioneer Investment Management Inc. grew its holdings in Gilead Sciences by 84.0% during the second quarter. Pioneer Investment Management Inc. now owns 3,493,148 shares of the biopharmaceutical company’s stock worth $247,245,000 after acquiring an additional 1,595,085 shares during the period. Neuberger Berman Group LLC grew its holdings in Gilead Sciences by 90.9% during the second quarter. Neuberger Berman Group LLC now owns 2,583,196 shares of the biopharmaceutical company’s stock worth $182,839,000 after acquiring an additional 1,229,916 shares during the period. Harbour Capital Advisors LLC grew its holdings in Gilead Sciences by 6,595.9% in the second quarter. Harbour Capital Advisors LLC now owns 1,221,804 shares of the biopharmaceutical company’s stock valued at $17,262,000 after purchasing an additional 1,203,557 shares during the period. Principal Financial Group Inc. grew its holdings in Gilead Sciences by 41.2% in the second quarter. Principal Financial Group Inc. now owns 3,909,105 shares of the biopharmaceutical company’s stock valued at $276,687,000 after purchasing an additional 1,140,112 shares during the period. Finally, Los Angeles Capital Management & Equity Research Inc. grew its holdings in Gilead Sciences by 75.0% in the first quarter. Los Angeles Capital Management & Equity Research Inc. now owns 2,549,292 shares of the biopharmaceutical company’s stock valued at $173,148,000 after purchasing an additional 1,092,206 shares during the period. 76.30% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Gilead Sciences, Inc. (NASDAQ:GILD) opened at $72.51 on Wednesday. Gilead Sciences, Inc. has a fifty-two week low of $63.76 and a fifty-two week high of $86.27. The company has a debt-to-equity ratio of 1.10, a current ratio of 3.68 and a quick ratio of 3.56. The firm has a market capitalization of $94,221.18, a PE ratio of 7.53, a PEG ratio of -1.21 and a beta of 1.13.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.27 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.13 by $0.14. The firm had revenue of $6.51 billion during the quarter, compared to the consensus estimate of $6.40 billion. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The firm’s revenue was down 13.2% compared to the same quarter last year. During the same period in the prior year, the business earned $2.75 EPS. analysts anticipate that Gilead Sciences, Inc. will post 8.53 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 28th. Shareholders of record on Friday, December 15th will be paid a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a yield of 2.87%. The ex-dividend date is Thursday, December 14th. Gilead Sciences’s dividend payout ratio is presently 23.69%.
In other Gilead Sciences news, insider John F. Milligan sold 220,000 shares of the company’s stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $72.88, for a total transaction of $16,033,600.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Gregg H. Alton sold 15,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $74.82, for a total value of $1,122,300.00. Following the sale, the executive vice president now directly owns 77,363 shares of the company’s stock, valued at $5,788,299.66. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 666,819 shares of company stock valued at $52,303,086. 1.30% of the stock is owned by company insiders.
TRADEMARK VIOLATION NOTICE: “Tiverton Asset Management LLC Has $6.58 Million Position in Gilead Sciences, Inc. (GILD)” was published by Daily Political and is the property of of Daily Political. If you are viewing this article on another site, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this article can be accessed at https://www.dailypolitical.com/2017/11/22/tiverton-asset-management-llc-has-6-58-million-position-in-gilead-sciences-inc-gild.html.
Several brokerages have commented on GILD. Leerink Swann raised their price objective on Gilead Sciences from $84.00 to $85.00 and gave the company a “market perform” rating in a report on Thursday, October 19th. BMO Capital Markets reissued an “outperform” rating and issued a $82.00 price objective (up from $72.00) on shares of Gilead Sciences in a report on Thursday, July 27th. BidaskClub lowered Gilead Sciences from a “buy” rating to a “hold” rating in a report on Wednesday, August 9th. Cowen and Company reissued an “outperform” rating and issued a $90.00 price objective on shares of Gilead Sciences in a report on Thursday, July 27th. Finally, Berenberg Bank reaffirmed a “buy” rating and issued a $86.00 price target (up from $79.00) on shares of Gilead Sciences in a research note on Sunday, August 20th. One equities research analyst has rated the stock with a sell rating, twelve have given a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $84.87.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.